Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells

Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various si...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Korean journal of physiology & pharmacology 2024-11
Hauptverfasser: Truong, Do Vinh, Yang, Beom-Seok, Song, Chiman
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title The Korean journal of physiology & pharmacology
container_volume
creator Truong, Do Vinh
Yang, Beom-Seok
Song, Chiman
description Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various side effects. Recent reports have suggested that kinase inhibitors are beneficial for relieving inflammation. Therefore, this study aimed to investigate the anti-inflammatory effects of LCB 03-0110, a multi-tyrosine kinase inhibitor, on representative cell-based models (HCE- 2 and Th17 cells) of DED. While tacrolimus and tofacitinib, two different anti-inflammatory drugs that have entered clinical trials for DED treatment, did not induce any anti-inflammatory responses in HCE-2 cells, LCB 03-0110 significantly suppressed the phosphorylation of P38 and ERK and reduced the expression levels of IL-6 and IL-8 in HCE-2 cells treated with either LPS or poly(I:C). Moreover, LCB 03-0110 notably decreased the expression level of IL-17A in Th17 cells in a dose-dependent manner, whereas tofacitinib promoted IL-17A production at low concentrations but inhibited its expression at concentrations greater than 1 μM. In addition, LCB 03-0110 was found to be non-toxic to both HCE-2 and Th17 cells. In conclusion, these results suggest that LCB 03-0110 would be a promising drug candidate for the treatment of DED because of its advantages over tacrolimus and tofacitinib.
doi_str_mv 10.4196/kjpp.24.166
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128821092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128821092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1296-77417218a96c3270373868da3c77e2b61031f213a546e244f410f29c010a5e0f3</originalsourceid><addsrcrecordid>eNo9kEtLAzEUhYMotlZX7iVLQabm3mSSybIWX1BwU9chTRM6dV4mM4v-e6dYXd3D5eNw-Ai5BTYXoOXj177r5ijmIOUZmSLTPOMFqnMyBUSZiRxwQq5S2jMmhZDikky4zrkGlU-JXTR9mZVNqGxd276NB-pD8K5PtA10tXyijGcMgNG2obuhtg11bWy8rajvyn7nq3KMttnSeohl4-majr_ORwqKOl9V6ZpcBFslf3O6M_L58rxevmWrj9f35WKVOUAtM6UEKITCauk4KsYVL2Sxtdwp5XEjgXEICNzmQnoUIghgAbVjwGzuWeAzcv_b28X2e_CpN3WZjgts49shGQ5YFAhM44g-_KIutilFH0wXy9rGgwFmjk7N0alBYUanI313Kh42td_-s38S-Q-S3m7E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128821092</pqid></control><display><type>article</type><title>Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells</title><source>KoreaMed Synapse</source><source>PMC (PubMed Central)</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Truong, Do Vinh ; Yang, Beom-Seok ; Song, Chiman</creator><creatorcontrib>Truong, Do Vinh ; Yang, Beom-Seok ; Song, Chiman</creatorcontrib><description>Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various side effects. Recent reports have suggested that kinase inhibitors are beneficial for relieving inflammation. Therefore, this study aimed to investigate the anti-inflammatory effects of LCB 03-0110, a multi-tyrosine kinase inhibitor, on representative cell-based models (HCE- 2 and Th17 cells) of DED. While tacrolimus and tofacitinib, two different anti-inflammatory drugs that have entered clinical trials for DED treatment, did not induce any anti-inflammatory responses in HCE-2 cells, LCB 03-0110 significantly suppressed the phosphorylation of P38 and ERK and reduced the expression levels of IL-6 and IL-8 in HCE-2 cells treated with either LPS or poly(I:C). Moreover, LCB 03-0110 notably decreased the expression level of IL-17A in Th17 cells in a dose-dependent manner, whereas tofacitinib promoted IL-17A production at low concentrations but inhibited its expression at concentrations greater than 1 μM. In addition, LCB 03-0110 was found to be non-toxic to both HCE-2 and Th17 cells. In conclusion, these results suggest that LCB 03-0110 would be a promising drug candidate for the treatment of DED because of its advantages over tacrolimus and tofacitinib.</description><identifier>ISSN: 1226-4512</identifier><identifier>EISSN: 2093-3827</identifier><identifier>DOI: 10.4196/kjpp.24.166</identifier><identifier>PMID: 39539175</identifier><language>eng</language><publisher>Korea (South)</publisher><ispartof>The Korean journal of physiology &amp; pharmacology, 2024-11</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39539175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Truong, Do Vinh</creatorcontrib><creatorcontrib>Yang, Beom-Seok</creatorcontrib><creatorcontrib>Song, Chiman</creatorcontrib><title>Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells</title><title>The Korean journal of physiology &amp; pharmacology</title><addtitle>Korean J Physiol Pharmacol</addtitle><description>Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various side effects. Recent reports have suggested that kinase inhibitors are beneficial for relieving inflammation. Therefore, this study aimed to investigate the anti-inflammatory effects of LCB 03-0110, a multi-tyrosine kinase inhibitor, on representative cell-based models (HCE- 2 and Th17 cells) of DED. While tacrolimus and tofacitinib, two different anti-inflammatory drugs that have entered clinical trials for DED treatment, did not induce any anti-inflammatory responses in HCE-2 cells, LCB 03-0110 significantly suppressed the phosphorylation of P38 and ERK and reduced the expression levels of IL-6 and IL-8 in HCE-2 cells treated with either LPS or poly(I:C). Moreover, LCB 03-0110 notably decreased the expression level of IL-17A in Th17 cells in a dose-dependent manner, whereas tofacitinib promoted IL-17A production at low concentrations but inhibited its expression at concentrations greater than 1 μM. In addition, LCB 03-0110 was found to be non-toxic to both HCE-2 and Th17 cells. In conclusion, these results suggest that LCB 03-0110 would be a promising drug candidate for the treatment of DED because of its advantages over tacrolimus and tofacitinib.</description><issn>1226-4512</issn><issn>2093-3827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLAzEUhYMotlZX7iVLQabm3mSSybIWX1BwU9chTRM6dV4mM4v-e6dYXd3D5eNw-Ai5BTYXoOXj177r5ijmIOUZmSLTPOMFqnMyBUSZiRxwQq5S2jMmhZDikky4zrkGlU-JXTR9mZVNqGxd276NB-pD8K5PtA10tXyijGcMgNG2obuhtg11bWy8rajvyn7nq3KMttnSeohl4-majr_ORwqKOl9V6ZpcBFslf3O6M_L58rxevmWrj9f35WKVOUAtM6UEKITCauk4KsYVL2Sxtdwp5XEjgXEICNzmQnoUIghgAbVjwGzuWeAzcv_b28X2e_CpN3WZjgts49shGQ5YFAhM44g-_KIutilFH0wXy9rGgwFmjk7N0alBYUanI313Kh42td_-s38S-Q-S3m7E</recordid><startdate>20241114</startdate><enddate>20241114</enddate><creator>Truong, Do Vinh</creator><creator>Yang, Beom-Seok</creator><creator>Song, Chiman</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241114</creationdate><title>Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells</title><author>Truong, Do Vinh ; Yang, Beom-Seok ; Song, Chiman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1296-77417218a96c3270373868da3c77e2b61031f213a546e244f410f29c010a5e0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Truong, Do Vinh</creatorcontrib><creatorcontrib>Yang, Beom-Seok</creatorcontrib><creatorcontrib>Song, Chiman</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Korean journal of physiology &amp; pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Truong, Do Vinh</au><au>Yang, Beom-Seok</au><au>Song, Chiman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells</atitle><jtitle>The Korean journal of physiology &amp; pharmacology</jtitle><addtitle>Korean J Physiol Pharmacol</addtitle><date>2024-11-14</date><risdate>2024</risdate><issn>1226-4512</issn><eissn>2093-3827</eissn><abstract>Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various side effects. Recent reports have suggested that kinase inhibitors are beneficial for relieving inflammation. Therefore, this study aimed to investigate the anti-inflammatory effects of LCB 03-0110, a multi-tyrosine kinase inhibitor, on representative cell-based models (HCE- 2 and Th17 cells) of DED. While tacrolimus and tofacitinib, two different anti-inflammatory drugs that have entered clinical trials for DED treatment, did not induce any anti-inflammatory responses in HCE-2 cells, LCB 03-0110 significantly suppressed the phosphorylation of P38 and ERK and reduced the expression levels of IL-6 and IL-8 in HCE-2 cells treated with either LPS or poly(I:C). Moreover, LCB 03-0110 notably decreased the expression level of IL-17A in Th17 cells in a dose-dependent manner, whereas tofacitinib promoted IL-17A production at low concentrations but inhibited its expression at concentrations greater than 1 μM. In addition, LCB 03-0110 was found to be non-toxic to both HCE-2 and Th17 cells. In conclusion, these results suggest that LCB 03-0110 would be a promising drug candidate for the treatment of DED because of its advantages over tacrolimus and tofacitinib.</abstract><cop>Korea (South)</cop><pmid>39539175</pmid><doi>10.4196/kjpp.24.166</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1226-4512
ispartof The Korean journal of physiology & pharmacology, 2024-11
issn 1226-4512
2093-3827
language eng
recordid cdi_proquest_miscellaneous_3128821092
source KoreaMed Synapse; PMC (PubMed Central); KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals
title Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-inflammatory%20effects%20of%20LCB%2003-0110%20on%20human%20corneal%20epithelial%20and%20murine%20T%20helper%2017%20cells&rft.jtitle=The%20Korean%20journal%20of%20physiology%20&%20pharmacology&rft.au=Truong,%20Do%20Vinh&rft.date=2024-11-14&rft.issn=1226-4512&rft.eissn=2093-3827&rft_id=info:doi/10.4196/kjpp.24.166&rft_dat=%3Cproquest_cross%3E3128821092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128821092&rft_id=info:pmid/39539175&rfr_iscdi=true